1. Signaling Pathways
  2. Immunology/Inflammation
  3. Interleukin Related

Interleukin Related

IL

Interleukins are a group of cytokines (secreted proteins and signaling molecules) that were first seen to be expressed by white blood cells (leukocytes). The function of the immune system depends in a large part on interleukins, and rare deficiencies of a number of them have been described, all featuring autoimmune diseases or immune deficiency. The majority of interleukins are synthesized by helper CD4 T lymphocytes, as well as through monocytes, macrophages, and endothelial cells. They promote the development and differentiation of T and B lymphocytes, and hematopoietic cells. Interleukin receptors on astrocytes in the hippocampus are also known to be involved in the development of spatial memories in mice.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P9949
    Reslizumab
    Antagonist 99.40%
    Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively.
    Reslizumab
  • HY-B0633C
    Hyaluronic acid (Mw:1000-2000Da)
    Inhibitor
    Hyaluronic acid (Mw:1000-2000Da) is a long-chain, unbranched polysaccharide with a molecular weight of 1000-2000 Dalton. Hyaluronic acid (Mw:1000-2000Da) regulates tissue homeostasis and stress resistance, exhibits a pro-inflammatory effect (while hyaluronic acid with high molecular weight exhibits an anti-inflammatory effect), and promotes angiogenesis and tissue remodeling. Hyaluronic acid (Mw:1000-2000Da) exhibits good biocompatible and biodegradable characteristics, that can be used in drug delivery systems and tissue engineering.
    Hyaluronic acid (Mw:1000-2000Da)
  • HY-B1051
    Flumethasone
    Modulator 99.84%
    Flumethasone (Flumetasone) is an orally active, high selective and potent glucocorticoid receptor (GR) agonist. Flumethasone activates GR to inhibit nuclear factor kappa B (NF-κB)-mediated pro-inflammatory cytokine production (TNF-α, IL-1β) and promotes anti-inflammatory gene expression (IL-10), while also regulating metabolic enzyme activity (tyrosine aminotransferase induction). Flumethasone is promising for research of inflammatory diseases, cancer, and endocrine regulation.
    Flumethasone
  • HY-130252
    YQ128
    Inhibitor 99.74%
    YQ128 is a potent and selective second-generation NLRP3 (NOD-like receptor P3) inflammasome inhibitor with an IC50 of 0.30 μM. YQ128 significantly and selectively suppresses the production of IL-1β, but not TNF-α, and it can cross the BBB to reach the CNS. YQ128 has anti-inflammatory activity. YQ128 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    YQ128
  • HY-18263C
    Elubrixin tosylate
    Antagonist 99.78%
    Elubrixin tosylate (SB-656933 tosylate) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin tosylate inhibits neutrophil CD11b upregulation (IC50 of 260.7 nM) and shape change (IC50 of 310.5 nM). Elubrixin tosylate has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation.
    Elubrixin tosylate
  • HY-139203
    IL-17 modulator 3
    Modulator 99.51%
    IL-17 modulator 3 is an IL-17 modulator (US20200247785A1). IL-17 modulator 3 can be used for the research of inflammation, cancer and autoimmune diseases.
    IL-17 modulator 3
  • HY-P9945A
    Mepolizumab (anti-IL5)
    Mepolizumab (anti-IL5) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma.
    Mepolizumab (anti-IL5)
  • HY-111346
    1-Linoleoyl Glycerol
    Inhibitor ≥98.0%
    1-Linoleoyl glycerol is a LpPLA2 inhibitor. 1-Linoleoyl glycerol acts as a precursor for synthesizing various functional lipids, such as phospholipids. 1-Linoleoyl glycerol mitigates inflammation induced by Apolipoprotein CIII (reduction of IL-6).
    1-Linoleoyl Glycerol
  • HY-P990217
    Anti-Mouse IL-23 p19 Antibody (G23-8)
    Inhibitor
    Anti-Mouse IL-23 p19 Antibody (G23-8) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse IL-23 p19.
    Anti-Mouse IL-23 p19 Antibody (G23-8)
  • HY-125130
    Hesperetin 7-O-glucoside
    Inhibitor 98.66%
    Hesperetin 7-O-glucoside is a typical flavonoid monoglucoside, which is an anti-inflammatory agent and an antihypertensive with orally active. Hesperetin 7-O-glucoside is a commonly used food adjuvant. Hesperetin 7-O-glucoside inhibits human intestinal maltase and human HMG-CoA reductase with Ki of 1.8 mM and 9.8 μM, respectively. Hesperetin 7-O-glucoside has antibacterial activity and can regulate intestinal flora and metabolic homeostasis in mice.
    Hesperetin 7-O-glucoside
  • HY-N2542
    Tubeimoside III
    Inhibitor 99.91%
    Tubeimoside III is a triterpenoid saponin. Tubeimoside III has anti-inflammatory and antitumor effects. Tubeimoside III has an LD50 of 15 mg/kg by intraperitoneal injection in ICR mice. Tubeimoside III can be used for the research of tumors and inflammatory diseases.
    Tubeimoside III
  • HY-P99287
    Elsilimomab
    Inhibitor 98.44%
    Elsilimomab (B-E8) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA).
    Elsilimomab
  • HY-N7674
    Angoline
    99.67%
    Angoline is a potent and selective IL6/STAT3 signaling pathway inhibitor with an IC50 of 11.56 μM. Angoline inhibits STAT3 phosphorylation and its target gene expression, and inhibits cancer cell proliferation.
    Angoline
  • HY-P99246
    Bermekimab
    Inhibitor
    Bermekimab (MABp1) is a human monoclonal antibody that targets interleukin-1alpa (IL-1α). Bermekimab prevents tumour-related inflammation.
    Bermekimab
  • HY-101259
    BMS-195614
    Inhibitor 99.5%
    BMS-195614 (BMS 614) is an orally active neutral RARα-selective antagonist with a Ki of 2.5 nM. BMS-195614 restores the expression of Bcl2. BMS-195614 inhibits the transactivation of NF-κB, AP-1 and PPAR. BMS-195614 downregulates the expression of IL-6 and VEGF. BMS-195614 reduces blue light-induced phototoxicity and inhibits cell migration. BMS-195614 modulates inflammation and angiogenesis.
    BMS-195614
  • HY-15507
    VGX-1027
    Inhibitor 99.76%
    VGX-1027 is an orally active isoxazole compound that exhibits various immunomodulatory properties. VGX-1027 targets macrophages, reducing the production of the proinflammatory mediators TNF-α, IL-1β, IL-10. VGX-1027 has antidiabetogenic effects by limiting cytokine-mediated immunoinflammatory events.
    VGX-1027
  • HY-122883
    BC-1471
    Inhibitor 99.69%
    BC-1471 is a STAMBP deubiquitinase inhibitor with an IC50 of 0.33 μM. BC-1471 can inhibit the activity of the NALP7 inflammasome. BC-1471 has anti-inflammatory activity and can be used for the research of inflammatory diseases.
    BC-1471
  • HY-101417
    Diethyl phosphate
    Inhibitor ≥98.0%
    Diethylphosphate (Diethyl phosphoric acid) is an orally active organophosphorus pesticides metabolite. Diethylphosphate can interfere with thyroid hormone-related mechanisms and affect intestinal microbes in rats.
    Diethyl phosphate
  • HY-18976
    UF010
    99.83%
    UF010 is a selective inhibitor of class I HDAC. UF010 has cytotoxicity to cancer cells and reduces neuroinflammation in the hippocampus. UF010 can be used for the research of neurological diseases.
    UF010
  • HY-P99533
    Urabrelimab
    Inhibitor 99.47%
    Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction.
    Urabrelimab
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.